Technion-Israel Institute of Technology scientists have published Friday a “breakthrough” discovery in Science magazine, that could lead to the development of effective new antibiotic types to fight bacterial disease.
Due to overuse of existing antibiotics and the growing resistance of bacteria to them, in the US alone, approximately 500,000 patients at hospitals contract a staph infection. It is the bacteria responsible for MRSA, for which there is no vaccine.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
The highly pathogenic Staphylococcus aureus bacteria is one of the five most common causes of hospital-acquired infections.
But all that could change, thanks to groundbreaking, for the first time, findings of unique amyloid fibrils through which the pathogenic and highly drug resistant Staphylococcus aureus bacterium attacks the human cells and immune system. The research could advance the discovery of new antibiotic with a novel mechanism of action that will attack key bacterial toxins.
The researcher team led by Assistant Professor Meytal Landau of the Faculty of Biology, discovered ‘ammunition’ that helps the bacteria: a novel form of an amyloid fibril whose three-dimensional structure was determined at atomic resolution, revealing the first-of-its-kind structure of this toxic fibril.
Amyloids, which are proteins notoriously known for their association with neuro-degenerative diseases such as Alzheimer’s and Parkinson’s, form a network of protein fibrils – somewhat similar to a spider web – characterized by an orderly and extremely stable structure. This stability enables the proteins to withstand extreme conditions in which ordinary proteins do not survive.
One of the best-known examples of this is “Mad Cow” disease, which broke out in England in 1986. Prof. Landau said that “This disease surprised the scientific community because its cause was not a virus, nor a bacterium, but a protein called Prion, possessing an amyloid-like structure.
It then became clear that a protein can be transmissible, and due to its stability, it infected human beings who consumed the contaminated beef – meaning, the protein did not break down in the stages of meat processing, cooking and digestion.”
The “Mad Cow” prion, like all amyloids discovered so far, belongs to a group possessing what is called a cross-ß structure. In the present study, an amyloid of a completely new structure was discovered, which was named cross-α.
“At some point we knew that we had found something unique, but only after several trips to cyclic particle accelerators (Synchrotrons) in Grenoble and Chicago were we successful in verifying its being a new type of amyloid,” said Prof. Landau. “Much more work was required before we could publish our findings, but from the very first moment, it was clear to us that what we had was a paradigm shift.”
“Resistance to antibiotics develops in bacteria due to evolutionary pressure – natural selection leads to the growth of bacteria which antibiotics are unable to kill,” she said. “If we reduce the pressure on the bacterium and don’t kill it but rather prevent its pathogenic aspects, the resistance will probably not rush to develop.”
She estimates that the new discovery will lead to the development of new antibiotic with a new action mechanism. Such drugs will inhibit the amyloid formation thereby neutralizing one of the important ‘weapons’ in the arsenal of this pathogenic bacterium. In her opinion, since this new antibiotic is not aimed at killing the bacterium but only reducing its toxicity to humans, it will not lead to a rapid development of bacterial resistance towards it.
When looking towards the future, Prof. Landau clarifies that “in academia itself, it’s difficult to carry out a full process of drug development due to the prohibitive cost entailed. Nevertheless, we can provide drug developers with scientific knowledge that will accelerate and lower the costs of the process. The present discovery is a stepping-stone in that respect. Now our challenge is to find the substance that will impede the cross-α fibril, thereby ‘disarming’ the bacterium.”
